Brookline Capital Acquisition Corp. (BCAC) to Combine with Apexigen in $205M Deal

Mar 18, 2022 INTEL by Nicholas Alan Clayton

Brookline (NASDAQ:BCAC) has entered into a definitive agreement to combine with Apexigen at a net-equity value of $205 million. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials. The combined company is expected to trade on the Nasdaq under the symbol “APGN” once the deal
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Brookline Capital Acquisition Corp. (BCAC) to Combine with Apexigen in $205M Deal

Brookline Capital Acquisition Corp. (BCAC) to Combine with Apexigen in $205M Deal

ByNicholas Alan Clayton